PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28344861-0	2017	Zoledronic acid boosts gammadelta T-cell activity in children receiving alphabeta+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.	Zoledronic Acid	0-15	CD19 molecule	Homo sapiens	89-93	
32714329-10	2020	Unlike standard CD19 CAR-T cells, gammadeltaCAR-T cells were able to target CD19 antigen negative leukemia cells, an effect that was enhanced after priming the cells with zoledronate.	Zoledronic Acid	171-182	CD19 molecule	Homo sapiens	76-80	
32477328-0	2020	Immune Modulation Properties of Zoledronic Acid on TcRgammadelta T-Lymphocytes After TcRalphabeta/CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia.	Zoledronic Acid	32-47	CD19 molecule	Homo sapiens	98-102	
32477328-2	2020	The use of zoledronic acid to enhance TcRgammadelta+ lymphocyte function after TcRalphabeta/CD19-cell depleted haplo-HSCT was tested in an open-label, feasibility, proof-of-principle study.	Zoledronic Acid	11-26	CD19 molecule	Homo sapiens	92-96	
32477328-16	2020	These data indicate that the use of zoledronic acid after TcRalphabeta/CD19-cell depleted haploHSCT is safe and may result in a lower incidence of acute GvHD, chronic GvHD, and TRM.	Zoledronic Acid	36-51	CD19 molecule	Homo sapiens	71-75	
28344861-1	2017	We demonstrated that gammadelta T cells of patients given HLA-haploidentical HSCT after removal of alphabeta+ T cells and CD19+ B cells are endowed with the capacity of killing leukemia cells after ex vivo treatment with zoledronic acid (ZOL).	Zoledronic Acid	221-236	CD19 molecule	Homo sapiens	122-126